Home › Research › Treatments
DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial
Robert A. Lasser, Susanne Ostrowitzki, Philip Scheltens, Merçé Boada, Bruno Dubois, Ernest E. Dorflinger, Bogdan Balas, Tania Nikolcheva et al.. Alzheimer s & Dementia, 2015-07-01
Topic: Drug trials: efficacy and safety
Plain-language summary
SCarlet RoAD (NCT01224106; WN25203), a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-year study of gantenerumab in prodromal AD, was the first global registration-enabling study using biomarker screening for entry and a single clinical endpoint for outcome. Dosing was terminated in December 2014 following a pre-planned futility analysis; patients continue to be followed. Efficacy data for 2-year completers (n=312) and all ITT safety data (n=797) are presented. Patients were 50–85 years old with MMSE scores ≥24, CDR-Global scores of 0.5 (memory box scores of 0.5 or 1.0) and evidence of amyloid pathology (CSF Aβ42 <600 ng/mL, Innotest), with cognition and functional performance largely preserved to exclude a diagnosis of AD dementia. Patients were randomized to monthly subcutaneous injections of placebo, or 105 mg or 225 mg gantenerumab, depending on their APOEe4 allele status (no APOEe4 homozygotes received 225 mg). Primary endpoint at 2 years was CDR-Sum of Boxes (SB) total score; secondary endpoints included ADAS-Cog 13, FAQ and MMSE. Biomarker results are presented separately. No differences in CDR-SB scores between placebo and gantenerumab treatment groups over 2 years were found, with similar findings for ADAS-Cog 13, FAQ and MMSE. PK/PD modeling showed an exposure-dependent trend for clinical benefit in patients that were predicted to have a faster rate of progression over the duration of the trial. Serious adverse events were reported in 19.5%, 17.3% and 16.9% of patients in the placebo, 105 mg and 225 mg gantenerumab arms, respectively. ARIA were dose- and APOEε4allele-dependent. Overall incidence of ARIA for placebo, 105 mg and 225 mg gantenerumab groups was 0.8%, 6.6% and 12.3% for ARIA-E, and 10.9%, 19.2% and 13.1% for ARIA-H, respectively. Additional exploratory analyses will be presented. Gantenerumab, a human anti-Aβ antibody with high affinity to aggregated Aβ, was well tolerated by patients with prodromal AD over the dose range tested in this dataset, one of the larger controlled datasets in prodromal AD patients available to date. No significant differences in primary efficacy endpoints between treatment arms were observed. Exploratory analyses are ongoing and will help guide further development of gantenerumab.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lasser, R. A., Ostrowitzki, S., Scheltens, P., Boada, M., Dubois, B., Dorflinger, E. E., et al. (2015). DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2015.08.153
Vancouver
Lasser RA, Ostrowitzki S, Scheltens P, Boada M, Dubois B, Dorflinger EE, et al. DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial. Alzheimer s & Dementia. 2015. doi:10.1016/j.jalz.2015.08.153.
BibTeX
@article{lasser2015-f0473682,
author = {Lasser, Robert A. and Ostrowitzki, Susanne and Scheltens, Philip and Boada, Merçé and Dubois, Bruno and Dorflinger, Ernest E. and Balas, Bogdan and Nikolcheva, Tania and others},
title = {{DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial}},
journal = {Alzheimer s \& Dementia},
year = {2015},
doi = {10.1016/j.jalz.2015.08.153},
url = {https://doi.org/10.1016/j.jalz.2015.08.153}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Biomarker results are presented separately.
- Overall incidence of ARIA for placebo, 105 mg and 225 mg gantenerumab groups was 0.8%, 6.6% and 12.3% for ARIA-E, and 10.9%, 19.2% and 13.1% for ARIA-H, respectively.
- No significant differences in primary efficacy endpoints between treatment arms were observed.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants312
- Effect sizeor 1.0; 19.5%; 17.3%
- Evidence strengthHigh
How this study scored 55/100
Published in a peer-reviewed journal. Scored zero for study design because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 32 of the 58 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 312 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 32 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 32 of the 58 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “monoclonal”
332 studies in the library carry the topic tag “monoclonal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.